IDiyas

For the Inventor, By the Inventor

Telford, PA, United States of America

Brian T Phillips

USPTO Granted Patents = 10

Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 60(Granted Patents)


Company Filing History:

goldMedal10 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1985-2008

Loading Chart...
10 patents (USPTO):Explore Patents
1. 7452893 - 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists (2008-11-18),
2. 7217716 - N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists (2007-05-15),
3. 7053089 - N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists (2006-05-30),
4. 6432976 - 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists (2002-08-13),
5. 5872138 - Thrombin inhibitors (1999-02-16),
6. 4808718 - Fused polycyclic and bridged compounds useful as calcium channel blockers (1989-02-28),
7. 4735956 - Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine (1988-04-05),
8. 4721708 - Cyclized N-substituted-tetrahydropyridine compounds and cardiovascular (1988-01-26),
9. 4670443 - Benzo(f)isoquinoline compounds useful as calcium entry blockers (1987-06-02),
10. 4532237 - Substituted and bridged pyridines useful as calcium channel blockers (1985-07-30),

Title: Brian T Phillips: A Pioneer in NMDA/NR2B Antagonist Research

Introduction

Brian T Phillips, based in Telford, PA, is a distinguished inventor with a remarkable portfolio of 10 patents. His contributions in the field of pharmacology have notably centered around NMDA/NR2B antagonists, showcasing his commitment to addressing significant neurological conditions.

Latest Patents

Among his latest innovations are two notable patents: the "4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists" and the "N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists." The first patent entails compounds that are effective as NMDA/NR2B antagonists useful for treating a range of neurological conditions such as pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, and ischemic brain injury including stroke. Meanwhile, the second patent focuses on compounds providing relief from pain by functioning as NMDA NR2B antagonists.

Career Highlights

Brian T Phillips is currently associated with Merck & Company, Inc., where he leverages his expertise in pharmacology and innovation. His extensive work in developing novel therapeutic compounds has placed him at the forefront of the scientific community, contributing to advancements in treating neurological disorders.

Collaborations

Throughout his career, Brian has collaborated with other notable professionals, including George D Hartman and Peter M Munson. These partnerships have not only enriched his research but also enabled the exchange of innovative ideas and solutions within the field.

Conclusion

Brian T Phillips exemplifies the spirit of innovation in pharmacology. His significant contributions, particularly in developing NMDA/NR2B antagonists, highlight the importance of continued research and development in addressing complex neurological challenges. As he advances his career at Merck & Company, Inc., his work will undoubtedly pave the way for future breakthroughs in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…